bioton holds 43.6% stake in sie Two things here:
(i) For a leading European Biotek to hold 43.6% stake in SIE is surely an resounding endorsement in their confidence in SIE's products and market penetration and potential reach; and more importantly sound financial management record (increasing revenues; commercial contracts; expect to record profits within 2 financial years of so); synergies with other leading biotek companies etc etc. Any further announcements of commercialisation deals will surely send the sp rocketing.
(ii) What would happen if say Bioton were to increase their current holdings to 50%??? (I'm no expert in this area at all, but would be very interested to hear views of experts on this.
Note that the scenario in point (ii) is pure speculation on my part. It assumes that Bioton held on to thier share acquisitions and secondly that they might contemplate raising their stakes in scigen. Let's face it an additional 7% from 43% to 50% is not beyond reasonable doubts
Thanks in advance, Pol.
- Forums
- ASX - By Stock
- SIE
- research on bio-hep b/sci-b vac/hepimmune
research on bio-hep b/sci-b vac/hepimmune, page-5
Featured News
Add SIE (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online